載入中
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
一般交易時段
US$8.56
+US$1.28 · +17.58%
盤中時間採用ET。市場資料可能有所延遲。
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
日內區間
目前US$8.56
52週區間
目前US$8.56
盤中時間採用ET。市場資料可能有所延遲。
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
日內區間
目前US$8.56
52週區間
目前US$8.56
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 281.5萬 USD | 698.3萬 USD | 802.1萬 USD | 956.1萬 USD | 913.35萬 USD |
| 銷售、一般及管理費用 | 928萬 USD | 966.4萬 USD | 1135.6萬 USD | 1352.7萬 USD | 808.07萬 USD |
| 營業費用 | 1727.5萬 USD | 2164.3萬 USD | 1680.6萬 USD | 2308.8萬 USD | 1721.41萬 USD |
| 利息收入 | 1000 USD | 8000 USD | 8.2萬 USD | 4.59萬 USD | 1.06萬 USD |
| 利息支出 | 94.9萬 USD | −24.4萬 USD | — | — | — |
| 折舊和攤銷 | — | 1.4萬 USD | 4000 USD | 4000 USD | 4126 USD |
| 營業利益 | −1727.5萬 USD | −2164.3萬 USD | −1680.6萬 USD | −2308.8萬 USD | −1721.41萬 USD |
| 淨利 | −1729.8萬 USD | −1979.1萬 USD | −1000.8萬 USD | −1774.8萬 USD | −1742.42萬 USD |
公司資料更新於 2026年10月15日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
